Grant ID RP150559
Awarded On May 20, 2015
Title Small Molecules to Perturb A Novel PPI Target For Chemotherapy
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization Texas A&M University
Principal Investigator/Program Director Kevin Burgess
Cancer Sites Leukemia
Contracted Amount $200,000
Lay Summary

Acute myeloid leukemia (AML) is a prevalent and aggressive form of blood cancer with a poor prognosis, particularly for older people. Most of the established drugs to treat AML are horribly toxic. However, some emerging treatments are likely to be better tolerated because they target a particular biochemical pathway that is switched on in cancer cells, making them more vulnerable to the drug than healthy ones. One such drug candidate in clinical trials, MLN4924, is unique insofar as it modifies a protein called NAE so that it is no longer able to bind to another one called NEDD8. Clinical data for MLN4924 is extremely promising, but cell studies indicate some forms of AML could be resistant....

Read More